Japanese clinical guidelines for myasthenia gravis: Putting into practice

Hiroyuki Murai

研究成果: Contribution to journalReview article査読

40 被引用数 (Scopus)

抄録

Treatment of myasthenia gravis has depended largely on high-dose corticosteroids for decades. Although this procedure remarkably reduced the mortality rate of myasthenia gravis, it highlighted issues such as the adverse-effects of steroids and reduction in quality of life. With the recent discovery of novel autoantibodies, a numbers of alternative therapeutic options have become available. The new Japanese clinical guidelines for myasthenia gravis were published in 2014, and they proposed a novel treatment strategy utilizing these therapeutic options, which might replace high-dose steroids. They also proposed a draft of new diagnostic criteria. The present review introduces the essence of these guidelines and shares the fundamental philosophy of the treatments that value the patients' quality of life.

本文言語英語
ページ(範囲)21-31
ページ数11
ジャーナルClinical and Experimental Neuroimmunology
6
1
DOI
出版ステータス出版済み - 2 1 2015

All Science Journal Classification (ASJC) codes

  • 神経科学(その他)
  • 免疫学
  • 免疫学および微生物学(その他)
  • 臨床神経学

フィンガープリント

「Japanese clinical guidelines for myasthenia gravis: Putting into practice」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル